We developed a flow-limed model for docetaxel plasma and tissue distribution following IP administration utilizing seven compartments; liver, intestine, kidney, slowly perfused tissues, rapidly perfused tissues, blood and an ip cavity. The liver, kidney and intestine were specific compartments utilized since these are the organs primarily responsible for metabolism and excretion of
ii docetaxel. An IP compartment was added to serve as a reservoir for absorption of docetaxel to the liver, intestine and directly into the blood. Grouping the remaining tissues into rapidly perfused and slowly perfused compartments minimized complexity of the model while still allowing for accurate prediction of a range of doses of docetaxel. A schematic representation of the PBPK model is shown in figure S1 . Since DTX was delivered to the peritoneal cavity, we assumed that the majority of the drug would be absorbed directly through the intestine, liver and blood. We assumed first order absorption of DTX, which was initially estimated from linear regression of the absorption phase of the DTX timecourse distribution. The absorbance rate constants used in the model were 1.2, 1.5 and 1.5 h -1 for the intestine, liver and blood respectively (Table S2) Figure S1 . Schematic representation of a PBPK model for docetaxel with IP administration. Values used for compartment parameters are shown in Table S1 and Table S2 . 
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